These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27484360)

  • 1. Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia.
    Jeziskova I; Semerad L; Dvorakova D; Janeckova V; Culen M; Kunetkova T; Mayer J; Racil Z
    Leuk Lymphoma; 2017 Mar; 58(3):746-748. PubMed ID: 27484360
    [No Abstract]   [Full Text] [Related]  

  • 2. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in acute myeloid leukemia.
    Kadia TM; Ravandi F; O'Brien S; Cortes J; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):139-51. PubMed ID: 25441110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsed
    Toruner GA; Thakral B
    Blood; 2019 Jan; 133(2):181. PubMed ID: 30630848
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
    Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
    Zidan MA; Kamal Shaaban HM; Elghannam DM
    Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
    Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience.
    Heiblig M; Sujobert P; Hayette S; Balsat M; Elhamri M; Salles G; Thomas X
    Leuk Res; 2019 Jan; 76():29-32. PubMed ID: 30529680
    [No Abstract]   [Full Text] [Related]  

  • 11. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.
    Marceau-Renaut A; Guihard S; Castaigne S; Dombret H; Preudhomme C; Cheok M
    Am J Hematol; 2015 May; 90(5):E93-4. PubMed ID: 25611491
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia.
    Schlenk RF; Döhner K
    Curr Opin Hematol; 2009 Mar; 16(2):98-104. PubMed ID: 19468271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
    Guenounou S; Delabesse E; Récher C
    Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of NPM1 mutated acute myeloid leukemia: A single-institution experience.
    Sayar H; Bashardoust P; Cripe L; Chakraborty S; Bai S
    Am J Hematol; 2017 Feb; 92(2):E17-E18. PubMed ID: 27813149
    [No Abstract]   [Full Text] [Related]  

  • 16. Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.
    Hofmann S; Götz M; Schneider V; Guillaume P; Bunjes D; Döhner H; Wiesneth M; Greiner J
    J Clin Oncol; 2013 Jan; 31(3):e44-7. PubMed ID: 23248243
    [No Abstract]   [Full Text] [Related]  

  • 17. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
    Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
    Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status.
    Bazarbachi A; Labopin M; Kharfan-Dabaja MA; Schwerdtfeger R; Volin L; Bourhis JH; Socié G; Daguindau E; Gedde-Dahl T; Rambaldi A; Karas M; Schlimok G; Blaise D; Chevallier P; Malard F; Schmid C; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Jan; 101(1):e34-7. PubMed ID: 26405153
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.
    Dvorakova D; Lengerova M; Pospisilova J; Palasek I; Mayer J
    Leukemia; 2009 Apr; 23(4):793-6. PubMed ID: 18830256
    [No Abstract]   [Full Text] [Related]  

  • 20. Time to reconsider the role of allogeneic transplantation for patients with acute myeloid leukemia and NPM1 mutation?
    Alyea EP
    J Clin Oncol; 2015 Feb; 33(5):381-2. PubMed ID: 25547505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.